Veerle Bieghs, Patrick J. van Gorp, Sofie M.A. Walenbergh, Marion J. Gijbels, Fons Verheyen, Wim A. Buurman, David E. Briles, Marten H. Hofker, Christoph J. Binder, Ronit Shiri‐Sverdlov – 15 February 2012 – Nonalcoholic steatohepatitis (NASH) is characterized by hepatic lipid accumulation combined with inflammation, which can ultimately progress into cirrhosis. Recently, we demonstrated that deletion of scavenger receptors (SRs) CD36 and SR‐A in hematopoietic cells reduced hepatic inflammation.

Kaname Yoshizawa, Akihiro Matsumoto, Tetsuya Ichijo, Takeji Umemura, Satoru Joshita, Michiharu Komatsu, Naoki Tanaka, Eiji Tanaka, Masao Ota, Yoshihiko Katsuyama, Kendo Kiyosawa, Masanori Abe, Morikazu Onji – 15 February 2012 – The long‐term outcome of patients with autoimmune hepatitis (AIH) in Japan has not been well‐defined. The aim of this study was to clarify the outcome of this disease over a long follow‐up period compared with that of the general Japanese population as well as that among patients. A total of 203 AIH patients were enrolled for a mean follow‐up period of 131 months.

Natalia Freitas, Jessica Salisse, Celso Cunha, Ilia Toshkov, Stephan Menne, Severin O. Gudima – 15 February 2012 – Hepatitis delta virus (HDV) is a natural subviral agent of human hepatitis B virus (HBV). HDV enhances liver damage during concomitant infection with HBV. The molecular pathogenesis of HDV infection remains poorly understood. To advance our understanding of the relationship between HDV infection and liver cancer, it was determined whether HDV could infect in vivo the cells of hepadnavirus‐induced hepatocellular carcinoma (HCC).

Shufeng Liu, Kevin D. McCormick, Wentao Zhao, Ting Zhao, Daping Fan, Tianyi Wang – 15 February 2012 – Hepatitis C virus (HCV) entry is a multiple‐step process involving a number of host factors and hence represents a promising target for new antiviral drug development. In search of novel inhibitors of HCV infection, we found that a human apolipoprotein E (apoE) peptide, hEP, containing both a receptor binding fragment and a lipid binding fragment of apoE specifically blocked the entry of cell culture grown HCV (HCVcc) at submicromolar concentrations.

John D. Ryan, Sandro Altamura, Emma Devitt, Sarah Mullins, Matthew W. Lawless, Martina U. Muckenthaler, John Crowe – 15 February 2012 – Pegylated interferon‐α (PEG‐IFN‐α) forms an integral part of the current treatment for hepatitis C virus (HCV) infection. PEG‐IFN‐α suppresses HCV production by augmenting the innate antiviral immune response. Recent studies have reported the induction of hepcidin, the iron regulatory hormone, by IFN‐α in vitro.

Celine S. Lages, Julia Simmons, Claire A. Chougnet, Alexander G. Miethke – 15 February 2012 – CD8 T‐lymphocytes are effector cells of cholangiocyte injury in human and in rhesus rotavirus (RRV)‐induced experimental biliary atresia (BA). Here we hypothesize that neonatal deficiency in CD25+CD4+ regulatory T cells (Tregs) leads to aberrant activation of hepatic T‐lymphocytes in BA.

Stephen A. Harrison, Fayez M. Hamzeh, Jian Han, Prashant K. Pandya, Muhammed Y. Sheikh, John M. Vierling – 15 February 2012 – Patients with chronic hepatitis C and insulin resistance are less likely to respond to anti‐hepatitis C virus (HCV) therapy and are at risk for more rapid fibrosis progression. Coadministration of pioglitazone with peginterferon/ribavirin improves insulin sensitivity and increases virologic response rates in insulin‐resistant HCV genotype 4 patients, but it is unclear whether this finding applies to genotype 1 patients.

Régine Truchi, Eve Gelsi, Faredj Cherikh, Albert Tran, Patrice Couzigou – 15 February 2012

Nathan M. Bass – 13 February 2012

Jeffrey S. Plotkin, Lynt B. Johnson, Vinod Rustgi, Paul C. Kuo – 13 February 2012